←Back to Expert Scholars
Translational Medicine / 转化医学Pembrolizumab dMMR, Pan-Tumor MSI-H
Luis A. Diaz Jr.
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Head, Division of Solid Tumor Oncology
100
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Luis Diaz led the KEYNOTE-158 and related trials that established pembrolizumab as the first tissue-agnostic FDA-approved therapy for MSI-H/dMMR tumors. His work transformed precision immunotherapy by defining MSI-H as a pan-tumor biomarker.
Share:
🧪Research Fields 研究领域
pembrolizumab MSI-H
KEYNOTE-158
tissue agnostic approval
dMMR immunotherapy
ctDNA MSI
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Luis A. Diaz Jr. 的研究动态
Follow Luis A. Diaz Jr.'s research updates
留下邮箱，当我们发布与 Luis A. Diaz Jr.（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment